OssiFi Therapeutics is developing market disruptive anti-sclerostin regenerative bone-biology products to address significant unmet needs in low back pain, fracture repair, and fracture prevention.
OssiFi's Key value drivers:
1) Oral competitor to Amgen’s injectable anti-sclerostin mAb product (Evenity®), and
2) Anti-sclerostin small molecule competitor to Medtronic’s INFUSE orthobiologic.
OssiFi is seeking investor capital and strategic partnerships to support its efforts to deliver best-in-class bone regenerative therapies to prevent and treat fractures in patients suffering from Osteogenesis Imperfecta, post-menopausal osteoporosis, and other fragile-bone disorders.
Company Details
- Address
- 11235 Mastin St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ossifi.com/
- Keywords
- Low Back Pain OSF-1, Osteogenesis Imperfecta, Osteoporosis, Trauma, Spinal Fusion, Sclerostin Inhibition, Small Molecules, Smart Tissue Scaffold.
- HQ
- Overland Park, Kansas
Ossifi Questions
Ossifi's website is https://www.ossifi.com/
Ossifi's LinkedIn profile is https://www.linkedin.com/company/ossifi
Ossifi's industry is
Biotechnology Research
Ossifi's top competitors are
Eccogene,
Heliona,
Osteogenix Inc,
Osteogenex, Inc,
Iron Prairie Ventures,
Cybership,
Montrium,
Osteogenics Biomedical, Inc.,
Orogen Therapeutics,
Jessica Freeman Hr.
Ossifi's categories are Biotechnology Research
